Full Press Release Details
ATLANTA , July 25, 2011 /PRNewswire/ -- Waters Corporation (NYSE: WAT ) today unveiled new technology solutions for increasing clinical laboratory efficiencies including the first CE Marked LC/MS/MS integrated solution for the quantification of everolimus (Certican®).
Being displayed in Waters booth #3136 are these exciting new products.
Educational Workshops
This year, Waters is sponsoring two scientific workshops which are designed to further the education of laboratory technicians, scientists, and chemists responsible for developing, implementing, and maintaining robust clinical assays. Each workshop features presentations from leading practitioners in the field of clinical chemistry.
Scientific Posters
Waters scientists and customers will be presenting several scientific posters at AACC including:
About Waters Clinical Business Operations
About Waters Corporation ( www.waters.com )
For over 50 years, Waters Corporation (NYSE: WAT ) has created business advantages for laboratory-dependent organizations by delivering practical and sustainable innovation to enable significant advancements in such areas as healthcare delivery, environmental management, food safety, and water quality worldwide.
Pioneering a connected portfolio of separations science, laboratory information management, mass spectrometry and thermal analysis, Waters technology breakthroughs and laboratory solutions provide an enduring platform for customer success.
With revenue of $1.64 billion in 2010 and 5,400 employees, Waters is driving scientific discovery and operational excellence for customers worldwide.
Waters, MassTrak, and ACQUITY are trademarks of Waters Corporation. Prograf is a registered trademark of Astellas Pharma. Certican is a registered trademark of Novartis AG.
SOURCE Waters Corporation